DrugId:  1
1. Name:  5-fluoro-2'-deoxycytidine
2. Groups:  Investigational
3. Description:  5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, and Urinary Bladder Neoplasms, among others.
4. Indication:  Not Available
DrugId:  2
1. Name:  APR-246
2. Groups:  Investigational
3. Description:  APR-246 has been used in trials studying the treatment of Prostatic Neoplasms, Hematologic Neoplasms, and Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.
4. Indication:  Not Available
DrugId:  3
1. Name:  Tetrahydrouridine
2. Groups:  Investigational
3. Description:  Tetrahydrouridine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Sickle Cell Disease, and Head and Neck Cancer, among others.
4. Indication:  Not Available
DrugId:  4
1. Name:  CP-547632
2. Groups:  Investigational
3. Description:  CP-547632 has been used in trials studying the treatment of Ovarian Cancer, Lung Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, and Fallopian Tube Cancer, among others.
4. Indication:  Not Available
DrugId:  5
1. Name:  MK-1496
2. Groups:  Investigational
3. Description:  MK-1496 has been used in trials studying the treatment of Neoplasms and Malignant.
4. Indication:  Not Available
DrugId:  6
1. Name:  Ombrabulin
2. Groups:  Investigational
3. Description:  Ombrabulin has been used in trials studying the treatment of Sarcoma, Neoplasms, Solid Tumor, Neoplasms, Malignant, and Advanced Solid Tumors, among others.
4. Indication:  Not Available
DrugId:  7
1. Name:  PF-04217903
2. Groups:  Investigational
3. Description:  PF-04217903 has been used in trials studying the treatment of Neoplasms.
4. Indication:  Not Available
DrugId:  8
1. Name:  MK-8776
2. Groups:  Investigational
3. Description:  Sch 900776 has been used in trials studying the treatment of Neoplasms, Hodgkin Disease, Adult Erythroleukemia, Lymphoma, Non-Hodgkin, and Myelogenous Leukemia, Acute, among others.
4. Indication:  Not Available
DrugId:  9
1. Name:  BCG vaccine
2. Groups:  Investigational
3. Description:  BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
4. Indication:  Not Available
DrugId:  10
1. Name:  Galunisertib
2. Groups:  Investigational
3. Description:  Galunisertib has been used in trials studying the basic science and treatment of Glioma, Neoplasms, Solid Tumor, GLIOBLASTOMA, and Prostate Cancer, among others.
4. Indication:  Not Available
DrugId:  11
1. Name:  Apaziquone
2. Groups:  Investigational
3. Description:  Apaziquone has been investigated for the treatment of Bladder Cancer and Bladder Neoplasms.
4. Indication:  Not Available
DrugId:  12
1. Name:  Berzosertib
2. Groups:  Investigational
3. Description:  Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
4. Indication:  Not Available
DrugId:  13
1. Name:  CPG-52852
2. Groups:  Investigational
3. Description:  852A has been used in trials studying the treatment of Melanoma, Neoplasms, Breast Cancer, Ovarian Cancer, and Cervical Cancer, among others.
4. Indication:  Not Available
DrugId:  14
1. Name:  Daniquidone
2. Groups:  Investigational
3. Description:  Daniquidone has been used in trials studying the treatment of Neoplasms.
4. Indication:  Not Available
DrugId:  15
1. Name:  Prednisone
2. Groups:  Approved, Vet approved
3. Description:  A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. [PubChem]
4. Indication:  For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis.
DrugId:  16
1. Name:  PF-04691502
2. Groups:  Investigational
3. Description:  PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
4. Indication:  Not Available
DrugId:  17
1. Name:  Carmustine
2. Groups:  Approved, Investigational
3. Description:  A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
4. Indication:  For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
DrugId:  18
1. Name:  Enfortumab vedotin
2. Groups:  Investigational
3. Description:  Enfortumab vedotin has been used in trials studying the treatment of Tumors, Neoplasms, and Medical Oncology.
4. Indication:  Not Available
DrugId:  19
1. Name:  LY-3039478
2. Groups:  Investigational
3. Description:  LY3039478 has been used in trials studying the treatment and basic science of LYMPHOMA, Neoplasms, Solid Tumor, COLON CANCER, and BREAST CANCER, among others.
4. Indication:  Not Available
DrugId:  20
1. Name:  RO-4987655
2. Groups:  Investigational
3. Description:  RO4987655 has been used in trials studying the treatment of Neoplasms.
4. Indication:  Not Available
DrugId:  21
1. Name:  PD-0325901
2. Groups:  Investigational
3. Description:  PD-0325901 has been used in trials studying the treatment and basic science of Melanoma, Solid Tumour, Solid Tumors, Advanced Cancer, and Breast Neoplasms, among others.
4. Indication:  Not Available
DrugId:  22
1. Name:  9-aminocamptothecin
2. Groups:  Investigational
3. Description:  Aminocamptothecin has been used in trials studying the treatment of Lymphoma, Gastric Cancer, Ovarian Cancer, Esophageal Cancer, and Ovarian Neoplasms, among others.
4. Indication:  Not Available
DrugId:  23
1. Name:  PF-477736
2. Groups:  Investigational
3. Description:  PF-00477736 has been used in trials studying the treatment of Neoplasms.
4. Indication:  Not Available
DrugId:  24
1. Name:  PU-H71
2. Groups:  Investigational
3. Description:  PU-H71 has been used in trials studying the treatment of LYMPHOMA, Solid Tumors, Metastatic Solid Tumor, and Myeloproliferative Neoplasms (MPN).
4. Indication:  Not Available
DrugId:  25
1. Name:  Afuresertib
2. Groups:  Investigational
3. Description:  Afuresertib has been used in trials studying the treatment of Cancer and Neoplasms, Haematologic.
4. Indication:  Not Available
